It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed ...
an E-selectin anatomist in phase 1. It's worth noting that this isn't Pfizer's first deal in SCD. In 2011 it paid $340 million for rights to rivipansel, a pan-selectin antagonist developed by ...
BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...
After hours: March 14 at 4:05:11 PM EDT Loading Chart for E ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback